Biotechnology

Techseriesinsight > Blog > News > Biotechnology

November 18, 2024
PRNewswire
Biotechnology

AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer

AbbVie (NYSE: ABBV) today announced the European Commission (EC) granted marketing authorization for ELAHERE® (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous...

November 18, 2024
Business Wire
Biotechnology

Cancer Targeted Technology Receives Fast Track $2.4M Grant to Develop an Innovative PSMA-Targeted Small Molecule Drug Conjugate for Prostate Cancer

Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on cancer diagnostics and therapeutics, announced that the National Cancer Institute awarded the Phase I portion ($400K) of the...

November 15, 2024
Business Wire
Biotechnology

Anaergia Awarded Contract to Operate and Maintain Rialto Bioenergy Solutions Facility in California

Anaergia Inc. (“Anaergia”, the “Company”, “we”, “us”, or “our”) (TSX: ANRG) announced today that its subsidiary, Anaergia Services LLC (“Anaergia Services”), has entered into a long-term Operations and Maintenance...

November 15, 2024
PRNewswire
Biotechnology

Immunovia presents model-development study results at meeting of the Collaborative Group of the Americas–Inherited Gastrointestinal Cancers

Immunovia (NASDAQ Stockholm: IMMNOV), the pancreatic cancer diagnostics company, will present results from the recently completed model-development study of the company’s next-generation test at the 2024 annual meeting of...

November 13, 2024
Business Wire
Biotechnology

GenSight Biologics Announces Submission of LUMEVOQ® Dossier to ANSM to Prepare for Restart of Early Access Program in France

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today...

November 13, 2024
Business Wire
Biotechnology

VIVOLTA Partners with Neurochase to Manufacture Electrospun Micro-Catheters Delivering Advanced CNS Therapies to the Brain

VIVOLTA, the medical electrospinning solutions provider, has signed a long-term partnership with Neurochase, the CNS (central nervous system) delivery platform specialist, to manufacture electrospun micro-catheters to deliver advanced therapies...

November 13, 2024
Business Wire
Biotechnology

CARMAT’s Aeson® Artificial Heart Is Gradually Becoming a Reference Solution for Bridge to Transplant in Europe

CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the...

November 12, 2024
Business Wire
Biotechnology

Pimicotinib Significantly Improved Outcomes for Patients with Tenosynovial Giant Cell Tumor in a Global Phase III Trial

Merck, a leading science and technology company, today announced that the Phase III MANEUVER trial of pimicotinib, an investigational medicine being developed by Abbisko Therapeutics Co., Ltd., met its...

November 8, 2024
PRNewswire
Biotechnology

Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

Harbour BioMed (the “Company”; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, today announced the...

November 8, 2024
PRNewswire
Biotechnology

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma

Carisma Therapeutics Inc. (Nasdaq: CARM) (“Carisma” or the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced positive pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor...